Hormone medicines
Letrozole
An estrogen-production inhibitor with established breast-cancer uses and important bone-health considerations.
Established medical uses
Also known as: Femara
Practical use
Applying the explained evidence
- Where it fits
- An estrogen-production inhibitor with established breast-cancer uses and important bone-health considerations.
- Put the information into practice
- The source describes clinical cancer care. It is not evidence that suppressing estrogen improves a healthy person’s physique or that symptoms can be managed by guessing hormone levels. Medicines with related mechanisms are not automatically interchangeable.
- Diagnosis before a number
- Write down the symptoms, the reason a test was ordered, and the medicines already used. An isolated hormone result is a question to interpret, not a stand-alone reason to add another medicine.
- Keep this limit in view
- The study examined body composition, exercise capacity, psychological function and metabolic measures. A large hormone shift was not equivalent to measured improvement in those endpoints; the population was not healthy athletes using multiple compounds.
Overview
Letrozole is a nonsteroidal aromatase inhibitor. It decreases estrogen production and is used in several postmenopausal breast-cancer settings, including after other treatments.
Risks and limitations
Hot flashes, fatigue, dizziness and joint or bone pain are reported. Treatment can worsen osteoporosis and increase fracture risk. Liver disease and cholesterol history matter; chest pain or sudden neurological symptoms require urgent care.
How to read this
The source describes clinical cancer care. It is not evidence that suppressing estrogen improves a healthy person’s physique or that symptoms can be managed by guessing hormone levels. Medicines with related mechanisms are not automatically interchangeable.
Research explained
Hormonal changes without demonstrated clinical improvement
Who was studied
42 men with BMI above 35 and low testosterone in a six-month double-blind placebo-controlled trial; 39 completed per protocol.
What was found
In the letrozole group, total testosterone rose from 8.6 to 21.5 nmol/L, LH from 3.3 to 8.8 U/L, and estradiol fell from 119.1 to 59.2 pmol/L. Significant improvements were not found in the predefined clinical endpoints.
What it cannot establish
The study examined body composition, exercise capacity, psychological function and metabolic measures. A large hormone shift was not equivalent to measured improvement in those endpoints; the population was not healthy athletes using multiple compounds.
Read the original studyA laboratory response is an intermediate result
A biochemical effect can be real while the hoped-for functional benefit remains unproven. This distinction is especially important when a medicine is described simply as a testosterone booster: the clinical goal and measured outcomes must be named.
Supporting sourceSources
Hormonal changes without demonstrated clinical improvement
Sources checked 2026-09-28.
General education; not a personal treatment plan.